Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis

Neuropsychopharmacology

Volumn 39, Issue 12, 2014, Pages 2891-2899

  Egerton, Alice ^a   Stone, James M ^a   Chaddock, Christopher A ^a   Barker, Gareth J ^a   Bonoldi, Ilaria ^a,b   Howard, Rachel M ^a   Merritt, Kate ^a   Allen, Paul ^a   Howes, Oliver D ^a   Murray, Robin M ^a   McLean, Mary A ^c   Lythgoe, David J ^a   O'Gorman, Ruth L ^a,d   McGuire, Philip K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID;

ADULT; BRAIN; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; METABOLISM; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

ADULT; BRAIN; FEMALE; FOLLOW-UP STUDIES; GLUTAMIC ACID; HUMANS; LONGITUDINAL STUDIES; MALE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

EID: 84939880226     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.143     Document Type: Article

References (51)

1. Allen P, Luigjes J, Howes OD, Egerton A, Hirao K, Valli I et al (2012). Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr Bull 38:1268-1276.
2. Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RW et al (2011). Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry 198:448-456.
3. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C et al (2010). 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry 15:629-636.
4. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
5. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A (2013a). Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol 16:471-475.
6. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, Diaz-Galvis L et al (2013b). Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 70:1057-1066.
7. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J et al (2011). Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36:1781-1791.
8. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK et al (2012a). Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology 37:2515-2521.
9. Egerton A, Fusar-Poli P, Stone JM (2012b). Glutamate and psychosis risk. Curr Pharm Des 18:466-478.
10. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L et al (2012). Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220-229.
11. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F et al (2013a). The psychosis highrisk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70:107-120.
12. Fusar-Poli P, Byrne M, Badger S, Valmaggia LR, McGuire PK (2013b). Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. Eur Psychiatry 28:315-326.
13. Fusar-Poli P, Stone JM, Broome MR, Valli I, Mechelli A, McLean MA et al (2011). Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 68:881-890.
14. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
15. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68.
16. Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR et al (2011). Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168:1311-1317.
17. Javitt DC (2007). Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69-108.
18. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:10.
19. Jones EG (1997). Cortical development and thalamic pathology in schizophrenia. Schizophr Bull 23:483-501.
20. Kargieman L, Santana N, Mengod G, Celada P, Artigas F (2008). NMDA antagonist and antipsychotic actions in cortico-subcortical circuits. Neurotox Res 14:129-140.
21. Konradi C, Heckers S (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97:153-179.
22. Kraguljac NV, White DM, Reid MA, Lahti AC (2013). Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 70:1294-1302.
23. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S et al (2008). Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 31:234-242.
24. Lodge DJ, Grace AA (2007). Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J Neurosci 27:11424-11430.
25. Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO et al (2010). Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry 15:308-318.
26. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE (2011). Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 39:120-129.
27. Mechelli A, Riecher-Rossler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ et al (2011). Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry 68:5.
28. Mullins PG, Chen H, Xu J, Caprihan A, Gasparovic C (2008). Comparative reliability of proton spectroscopy techniques designed to improve detection of J-coupled metabolites. Magn Reson Med 60:964-969.
29. Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A et al (2013). Long-term follow-up of a group at ultra high risk ('Prodromal') for psychosis: the PACE 400 study. JAMA Psychiatry 70:793-802.
30. Nelson B, Yung AR (2010). Can clinicians predict psychosis in an ultra high risk group? Aust N Z J Psychiatry 44:625-630.
31. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
32. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
33. Phillips LJ, Yung AR, McGorry PD (2000). Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust N Z J Psychiatry 34 (Suppl): S164-S169.
34. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH et al (2006). First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11:118-119.
35. Provencher SW (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679.
36. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24:330-334.
37. Simon AE, Borgwardt S, Riecher-Rossler A, Velthorst E, de Haan L, Fusar-Poli P (2013). Moving beyond transition outcomes: metaanalysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res 209:266-272.
38. Snyder J, Wilman A (2010). Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T. J Magn Reson 203:66-72.
39. Sodhi MS, Simmons M, McCullumsmith R, Haroutunian V, Meador-Woodruff JH (2011). Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry 70:646-654.
40. Stone JM, Bramon E, Pauls A, Sumich A, McGuire PK (2010). Thalamic neurochemical abnormalities in individuals with prodromal symptoms of schizophrenia - relationship to auditory event-related potentials. Psychiatry Res 183:174-176.
41. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ et al (2009a). Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66:533-539.
42. Stone JM, Fusar-Poli P (2009b). Abnormal thalamic glutamate and liability to psychosis: state or trait marker? Schizophr Res 115:94-95.
43. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944-1946.
44. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK et al (2007). Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 191:325-334.
45. Tibbo P, Hanstock C, Valiakalayil A, Allen P (2004). 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 161:1116-1118.
46. Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR (2000). Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci 12:1420-1430.
47. Wood SJ, Kennedy D, Phillips LJ, Seal ML, Yucel M, Nelson B et al (2010). Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 52:62-68.
48. Yung AR, Nelson B, Thompson A, Wood SJ (2010). The psychosis threshold in Ultra High Risk (prodromal) research: is it valid? Schizophr Res 120:1-6.
49. Yung AR, Phillips LJ, Yuen HP, McGorry PD (2004). Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res 67:131-142.
50. Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B et al (2007). Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 33:673-681.
51. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M et al (2005). Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust N Z J Psychiatry 39:964-971.